procured 1,600 metric tons of nickel sulfate incorporated into a constituent material for the battery cell production facility, of which 75 percent (1,200/ 1,600 metric tons) is FEOC-compliant. Since the lithium hydroxide is the least compliant applicable critical mineral or component, M allocates the FEOCcompliant lithium hydroxide mass to 50 percent or 500,000 (50 percent * 1,000,000) of the total battery cells, and to battery cells that contain FEOCcompliant cathode electrodes and have been allocated FEOC-compliant nickel sulfate. Under paragraph (c)(2)(ii)(E) of this section, the quantity of FEOCcompliant battery cells is limited by the applicable critical mineral (lithium hydroxide) that has the lowest percentage (50 percent) of FEOCcompliant supply.

(E) Under paragraph (c)(2) of this section, M must use a serial number or other identification system to track the 500,000 FEOC-compliant battery cells to 500 (500,000/1,000) specific batteries.

(F) Under paragraph (d)(1) of this section, a compliant-battery ledger must be established for calendar year 2025. For purposes of paragraph (d)(2)(i) of this section. M determines that it will manufacture 500 batteries for calendar year 2025 that are FEOC-compliant. Under paragraph (d)(2)(ii) of this section, M attests to the 500 FEOCcompliant batteries and provides the basis for the determination, including attestations, certifications, and documentation demonstrating compliance with paragraphs (b) and (c) of this section. Once the IRS, with analytical assistance from the DOE, has approved the number, a compliantbattery ledger is established with a balance of 500 FEOC-compliant batteries.

(h) Severability. The provisions of this section are separate and severable from one another. If any provision of this section is stayed or determined to be invalid, it is the agency's intention that the remaining provisions will continue in effect.

(i) *Applicability date.* This section applies to new clean vehicles placed in service after December 31, 2023.

Douglas W. O'Donnell,

Deputy Commissioner for Services and Enforcement.

[FR Doc. 2023–26513 Filed 12–1–23; 8:45 am] BILLING CODE 4830–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

42 CFR Part 93

RIN 0937-AA12

Public Health Service Policies on Research Misconduct; Extension of Comment Period

AGENCY: U.S. Department of Health and Human Services (HHS).

ACTION: Proposed rule; Extension of comment period.

SUMMARY: The Department of Health and Human Services (HHS), Office of the Secretary, Office of the Assistant Secretary for Health (OASH), Office of Research Integrity (ORI) is extending the comment period by 30 days for the proposed rule entitled "Public Health Service Policies on Research Misconduct" published in the **Federal Register** on October 6, 2023. Public comments must be submitted on or before January 4, 2024.

DATES: HHS is extending the comment period by 30 days on the proposed rule published October 6, 2023 at 88 FR 69583. Submit comments on or before January 4, 2024.

ADDRESSES: For efficient management of comments, HHS requests that all comments be submitted electronically to *https://www.regulations.gov* (referred to hereafter as "*regulations.gov*"). In commenting, please refer to the Regulatory Information Number (RIN) [0937–AA12].

Instructions: Enter the RIN in the search field at https:// www.regulations.gov and click on "Search." To view the proposed rule, click on the title of the rule. To comment, click on "Comment" and follow the instructions. If you are uploading multiple attachments into *regulations.gov*, please number and label all attachments; https:// www.regulations.gov will not automatically number them. All relevant comments will be posted without change to https:// www.regulations.gov, including any personal information provided. For detailed instructions on submitting comments and additional information on the rulemaking process, see the "Public Participation" heading of the SUPPLEMENTARY INFORMATION section in the Notice of Proposed Rulemaking published at 88 FR 69583.

Docket: For access to the docket to read comments received, please go to *https://www.regulations.gov.*

FOR FURTHER INFORMATION CONTACT: Sheila Garrity, JD, MPH, MBA, Office of Research Integrity, 1101 Wootton Parkway, Suite 240, Rockville, MD 20852; telephone 240–453–8200.

SUPPLEMENTARY INFORMATION: The Agency is extending the deadline to comment on the proposed rule entitled "Public Health Service Policies on Research Misconduct" published in the **Federal Register** on October 6, 2023 (88 FR 69583), in response to requests for an extension to allow interested persons additional time to submit comments.

Dated: November 29, 2023.

Xavier Becerra,

Secretary, Department of Health and Human Services.

[FR Doc. 2023–26590 Filed 12–1–23; 8:45 am] BILLING CODE 4150–31–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of Inspector General

42 CFR Part 1001

Solicitation of Proposals for New and Modified Safe Harbors and Special Fraud Alerts

AGENCY: Office of Inspector General (OIG), Department of Health and Human Services (HHS or the Department). **ACTION:** Notification of intent to develop regulations.

SUMMARY: In accordance with section 205 of the Health Insurance Portability and Accountability Act of 1996 (HIPAA), this annual notification solicits proposals and recommendations for developing new, or modifying existing, safe harbor provisions under section 1128B(b) of the Social Security Act (the Act), the Federal anti-kickback statute, as well as developing new OIG Special Fraud Alerts.

DATES: To ensure consideration, public comments must be received no later than 5 p.m. on February 2, 2024.

ADDRESSES: In commenting, please refer to file code OIG–1123–N. Because of staff and resource limitations, we cannot accept comments by fax transmission. You may submit comments in one of two ways (no duplicates, please):

1. *Electronically*. You may submit comments electronically at *https:// www.regulations.gov*. Follow the "Submit a comment" instructions and refer to file code OIG-1123-N.

2. By regular, express, or overnight mail. You may send written comments to the following address: OIG, Regulatory Affairs, HHS, Attention: OIG-1123-N, Room 5628, Cohen Building, 330 Independence Avenue SW, Washington, DC 20201. Please